Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures

• Published in: International journal of gynecological cancer Vol. 16; no. 2; pp. 490 - 495
• Main Authors: Tentes, A-A K, Mirelis, C G, Markakidis, S K, Bekiaridou, K A, Bougioukas, I G, Xanthoulis, A I, Tsalkidou, E G, Zafiropoulos, G H, Nikas, I H
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.03.2006
• Subjects: Adenocarcinoma, Clear Cell - drug therapy; Adenocarcinoma, Clear Cell - mortality; Adenocarcinoma, Clear Cell - surgery; Adenocarcinoma, Mucinous - drug therapy; Adenocarcinoma, Mucinous - mortality; Adenocarcinoma, Mucinous - surgery; Adult; Aged; Aged, 80 and over; Carcinoma, Papillary - drug therapy; Carcinoma, Papillary - mortality; Carcinoma, Papillary - surgery; Chemotherapy; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous - drug therapy; Cystadenocarcinoma, Serous - mortality; Cystadenocarcinoma, Serous - surgery; Female; Gastric cancer; Hospital Mortality; Humans; Lymphatic Metastasis - pathology; Medical prognosis; Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - surgery; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - mortality; Peritoneal Neoplasms - surgery; Postoperative Complications - etiology; Postoperative Complications - mortality; Prognosis; Retrospective Studies; Surgery; Survival Rate; Survivors; Time Factors; Treatment Outcome
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-00009577-200603000-00005

The impact of cytoreductive surgery with standard peritonectomy procedures has not been extensively assessed in the treatment of advanced ovarian cancer. The aims of the study are to report the long-term results of patients with advanced ovarian cancer undergoing cytoreductive surgery with standard peritonectomy procedures and to identify the prognostic indicators that may affect outcome. The records of 74 women with advanced ovarian cancer were retrospectively reviewed. Clinical indicators were correlated to survival. The hospital mortality and morbidity rates were 13.5% and 28.4%, respectively. Complete or near-complete cytoreduction was possible in 78.4% of the patients. Overall 10-year survival rate was 52.5%. Complete cytoreductive surgery, small-volume tumor, low-grade tumor, the absence of distant metastases, the use of systemic adjuvant chemotherapy, performance status >70%, and limited extent of peritoneal carcinomatosis were favorable indicators of survival. Complete cytoreduction (P= 0.000) and treatment with systemic chemotherapy (P= 0.001) independently influenced survival. Recurrence was recorded in 37.8% of the patients and was independently influenced by the tumor grade (P= 0.037). Cytoreductive surgery with standard peritonectomy procedures followed by adjuvant chemotherapy offers long-term survival in women with advanced ovarian cancer who have limited peritoneal carcinomatosis and no distant and irresectable metastases.